Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1356576 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $47.73Day +1.60%Mkt cap $2.8B1Y +42.9%Off 52W high −20.0%Vol (1Y) 37.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,586 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.4% of sh out |
| Days to cover5.1d |
| 13F net flow (QoQ)+1.16% |
| Top-10 13F concentration51.0% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$776.8M |
| Earnings (TTM)-$29.0M |
| ROE−3.7% |
| Net margin−5.4% |
| ROIC−5.2% |
| Sales growth 3Y2.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−4.0% |
| 1Y+42.9% |
| 3Y+56.9% |
| 5Y+70.3% |
| Since incept. (ann.)+17.4% |
Total return through 2026-07-28 · series begins 2020-04-01. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)37.0% |
| Ann. volatility (3Y)36.2% |
| Sharpe (1Y)1.16 |
| Sharpe (3Y)0.61 |
| Max drawdown (1Y)−23.5% |
| Max drawdown (3Y)−31.0% |
| Beta (3Y vs SPY)0.70 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 8.8M | $455M | 15.16% | +0.7% |
| MILLENNIUM MANAGEMENT LLC | 3.3M | $171M | 5.71% | +25.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.2M | $167M | 5.58% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | $128M | 4.25% | new |
| DIMENSIONAL FUND ADVISORS LP | 2.3M | $119M | 3.97% | −14.9% |
| STATE STREET CORP | 2.3M | $118M | 3.94% | +3.1% |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.0M | $105M | 3.51% | −11.7% |
| ARMISTICE CAPITAL, LLC | 1.9M | $98M | 3.27% | −31.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 100.3% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 4,721,234 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.04 | — | $207.7M | +38.6% |
| 2025-12-31 | 2026-02-24 | — | — | $211.6M | +21.5% |
| 2025-09-30 | 2025-11-04 | −$0.80 | −215.9% | $192.1M | +9.3% |
| 2025-06-30 | 2025-08-05 | $0.40 | +11.1% | $165.5M | −1.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
